This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Good day, ladies and gentlemen, and welcome to the First Quarter 2019 TESSCO Technologies Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
SWIR SW TESS
Sierra Wireless, Inc. (SWIR - Free Report) recently unveiled the new AirLink MG90 high-performance LTE-Advanced Pro multi-network vehicle router, designed specifically to provide secure and constant connectivity for mission critical applications. This is the first device to be deemed FirstNet Ready. Understanding FirstNet To better understand the motive behind Sierra’s newly-launched router, let us first talk about what FirstNet is.
SWIR MSI CMTL SW PII
Our connection to the internet took on a new and more involved form when much of the connectivity moved from the PC to the smartphone. This ushered in a whole host of applications that changed the way we live.
SWIR SWKS TXN ARW SW NYTAB MCHP INTC
Disclaimer: This material is furnished by Lerna Capital LLC or affiliates (collectively “Lerna”). This material is for information purposes only and is not an offer or a solicitation to subscribe for or purchase the securities mentioned. This material is not intended to provide a sufficient basis on which to make an investment decision. All market and commercial data in this thesis are not warranted as to completeness or accuracy.
SWIR INSG SW MIFI
Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2018 TESSCO Technologies Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
SWIR SW TESS
Where the portfolio stood at the time of my last update, where it stands today and recent developments on the stocks held therein.
FB DB FFRMF ACBFF CGNX SW NVDA SWIR SHLD SWKS TWMJF WEED AAPL WELL CCI.PRA CCI ATT SNNVF ATTBF NXTTF STM ACB V FTMDF GOOGL JNJ MU TSLA MSFT SHLDW APHQF
Good afternoon. My name is Sheryl, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sierra Wireless First Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its treatment of major depressive disorder (MDD). The acceptance comes after the FDA had initially issued a "refusal to file" letter for the MDD treatment, ALKS 5461, on March 30. The stock had plunged 22% on April 2, when the news of the letter was released.
SWIR MRVL UA ALKS HIMX EDGE UAA SW LVS PETS
This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here.
SWIR EXFO SW
After opening higher on the back of Monday’s strong rebound, stocks tumbled into the red again on Tuesday afternoon. Tech companies led the day’s selloff, with investors continuing to ditch internet companies like Facebook (FB - Free Report) , Twitter (TWTR - Free Report) , and Alphabet (GOOGL - Free Report) in the wake of data privacy concerns.
SWIR FB TXN GOOGL TWTR SW SGH RHT
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TSX:SW / Sierra Wireless on message board site Silicon Investor.